Dana-Farber/Harvard Cancer Center Selects the OnCore® Clinical Research Management System
The search for an integrated clinical research management system came to an end in February when
“At some level, we’ve been looking for a product over a decade,” said Jeffrey W. Clark, MD, Medical Director of Clinical Trials Operations at DF/HCC. Unfortunately, a system that was sophisticated enough to handle the complexity of Dana-Farber/Harvard Cancer Center’s seven-institution consortium did not exist until recently.
“In many ways, we had gone as far as we could in improving the operation. What was really missing were the integrated systems that would give us the automation, information, and management decision making tools to take our clinical trials program to the next level,” said Beverly Ginsburg-Cooper, MBA, Associate Director for Administration at DF/HCC and Senior VP for Research at Dana-Farber Cancer Institute.
Currently, DF/HCC uses informatics to support its clinical research operation. However, these systems are not fully integrated and there are opportunities to eliminate the duplication of effort and enhance the flow of data.
DF/HCC is comprised of seven separate independent institutions that function as a cohesive consortium. The center has a unified clinical trials structure with a single IRB, a single Protocol Review and Monitoring System, a single Data Safety and Monitoring Process, a single set of operating policies and procedures, and a centralized clinical trials infrastructure to support these functions. Additionally, the center has coordinated budgeting and contracting processes. But, each institution coordinates its own data management activities independently.
Immediately, the goal is to start using
Working Together to Improve Cancer Research and Care
The implementation of OnCore was kicked-off earlier this month at DF/HCC, and the center has already started participating in user community events and activities through Onsemble, a community comprised of OnCore users and others concerned with improving clinical research operations.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025